What is the 13F Pro Quality Score for CRDF?

13F Pro ranks Cardiff Oncology, Inc. (CRDF) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRDF's current score at https://13fpro.ai/company/CRDF (free sign-up required for the full ranking).

Where does 13F Pro source CRDF data?

All Cardiff Oncology, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cardiff Oncology, Inc. files with the SEC under CIK 1213037. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRDF in?

Cardiff Oncology, Inc. (CRDF) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRDF research updated on 13F Pro?

CRDF's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cardiff Oncology, Inc.(CRDF)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1213037 CRDF stock profile & AI dashboard →

13F Pro Quality Score

9.8/100

Rank #2,912 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CRDF Scores 10/100

exact factor attribution · 2026-09-11

CRDF's composite is driven by earnings growth, held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.2 pts

95th pct

Institutional flow

-2.3 pts

4th pct

Shareholder dilution

-2.4 pts

2th pct

Earnings quality

-3.9 pts

11th pct

Capital efficiency

-4.4 pts

6th pct

Profitability

-7.2 pts

2th pct

Scale

-7.2 pts

2th pct

Free cash flow

-7.3 pts

1th pct

Revenue growth

-7.8 pts

11th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in CRDF

Events flagged as statistical outliers against CRDF's own multi-year baseline — not fixed dollar thresholds.

Insider cluster2026-07-14
2 insiders bought $1,049,999 of CRDF in 30 days — 3.8σ above this company's 2-year norm
View source filing →

CRDF Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Cardiff Oncology, Inc. (CRDF), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRDF at 9.8/100 on a 32-signal composite quality model, placing it at rank #2,912 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Cardiff Oncology, Inc. reports quarterly revenue of $104.0K, net income of $-9.2M. Top institutional holders of CRDF by reported 13-F value include Laurion Capital Management, VANGUARD CAPITAL MANAGEMENT, PFIZER, based on the most recent SEC filings. CRDF trades on the Nasdaq exchange and files with the SEC under CIK 1213037. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRDF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cardiff Oncology, Inc. directly from SEC EDGAR. Cardiff Oncology, Inc.'s 13F Pro composite quality score has ranged between 5 and 27 since 2021, currently 9.8 — a declining long-term trajectory across 20 quarterly and live scoring snapshots.

Revenue

Q2 2026

$104.0K

Net Income

Q2 2026

$-9.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-13.2% YoY

$593.0KFY 2025

FY22 $386.0KFY23 $488.0KFY24 $683.0KFY25 $593.0K

Net Income

-0.9% YoY

$-45.9MFY 2025

FY22 $-38.7MFY23 $-41.4MFY24 $-45.4MFY25 $-45.9M

Operating Income

-0.6% YoY

$-49.0MFY 2025

FY22 $-39.9MFY23 $-45.4MFY24 $-48.7MFY25 $-49.0M

EPS (Diluted)

+27.4% YoY

$-0.69FY 2025

FY22 $-0.89FY23 $-0.93FY24 $-0.95FY25 $-0.69

Total Assets

-36.3% YoY

$61.9MFY 2025

FY22 $116.2MFY23 $81.6MFY24 $97.2MFY25 $61.9M

Op. Cash Flow

-0.6% YoY

$-37.9MFY 2025

FY22 $-33.8MFY23 $-30.9MFY24 $-37.7MFY25 $-37.9M

Free Cash Flow

-0.5% YoY

$-38.0MFY 2025

FY22 $-34.8MFY23 $-31.5MFY24 $-37.8MFY25 $-38.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$593.0K -13.2%	$683.0K +40.0%	$488.0K +26.4%	$386.0K +7.5%	$359.0K -1.9%	$366.0K
Net Income	$-45.9M -0.9%	$-45.4M -9.6%	$-41.4M -7.1%	$-38.7M -36.8%	$-28.3M -46.5%	$-19.3M
Operating Income	$-49.0M -0.6%	$-48.7M -7.1%	$-45.4M -13.8%	$-39.9M -38.3%	$-28.9M -51.2%	$-19.1M
EPS (Diluted)	$-0.69 +27.4%	$-0.95 -2.2%	$-0.93 -4.5%	$-0.89 -21.9%	$-0.73 +32.4%	$-1.08
Total Assets	$61.9M -36.3%	$97.2M +19.1%	$81.6M -29.7%	$116.2M -22.3%	$149.5M +11.0%	$134.7M
Operating Cash Flow	$-37.9M -0.6%	$-37.7M -22.0%	$-30.9M +8.7%	$-33.8M -46.8%	$-23.0M -41.2%	$-16.3M
Free Cash Flow	$-38.0M -0.5%	$-37.8M -20.0%	$-31.5M +9.6%	$-34.8M -49.8%	$-23.2M -40.7%	$-16.5M

Get alerted when CRDF's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cardiff Oncology, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRDF

Laurion Capital Management LP
$4.0M3,098,299 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.8M2,895,592 sh
PFIZER INC
$3.0M2,411,575 sh
FRANKLIN RESOURCES INC
$1.6M1,205,803 sh
BlackRock, Inc.
$1.3M972,873 sh
BLAIR WILLIAM & CO/IL
$1.2M912,513 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.1M820,062 sh
UBS Group AG
$830.3K638,699 sh
JANE STREET GROUP, LLC
$790.3K607,900 sh
VANGUARD FIDUCIARY TRUST CO
$533.8K410,602 sh

Fund	Value	Shares
Laurion Capital Management LP	$4.0M	3,098,299
VANGUARD CAPITAL MANAGEMENT LLC	$3.8M	2,895,592
PFIZER INC	$3.0M	2,411,575
FRANKLIN RESOURCES INC	$1.6M	1,205,803
BlackRock, Inc.	$1.3M	972,873
BLAIR WILLIAM & CO/IL	$1.2M	912,513
GEODE CAPITAL MANAGEMENT, LLC	$1.1M	820,062
UBS Group AG	$830.3K	638,699
JANE STREET GROUP, LLC	$790.3K	607,900
VANGUARD FIDUCIARY TRUST CO	$533.8K	410,602

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRDF on your watchlist

Track score changes the day Cardiff Oncology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRDF a good stock to buy?

13F Pro's AI-powered analysis of Cardiff Oncology, Inc. (CRDF) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRDF are available on the CRDF stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CRDF is classified as a small company.

Which hedge funds own CRDF?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRDF. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cardiff Oncology, Inc.'s investment landscape.